Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

T cells take aim at a ubiquitous autoantigen in multiple sclerosis.

Sabatino JJ Jr, Zamvil SS.

Sci Transl Med. 2018 Oct 10;10(462). pii: eaau8826. doi: 10.1126/scitranslmed.aau8826. Review.

PMID:
30305455
2.

Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease.

Häusler D, Häusser-Kinzel S, Feldmann L, Torke S, Lepennetier G, Bernard CCA, Zamvil SS, Brück W, Lehmann-Horn K, Weber MS.

Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9773-9778. doi: 10.1073/pnas.1810470115. Epub 2018 Sep 7.

3.

The Evolving Mechanisms of Action of Glatiramer Acetate.

Prod'homme T, Zamvil SS.

Cold Spring Harb Perspect Med. 2018 Feb 12. pii: a029249. doi: 10.1101/cshperspect.a029249. [Epub ahead of print]

PMID:
29440323
4.

Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α.

Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H, Duan H, Ma P, Zhang L, Zamvil SS, Hidalgo J, Zhang Z, O'Rourke DM, Dahmane N, Brem S, Mou Y, Gong Y, Fan Y.

Nat Commun. 2018 Feb 8;9(1):559. doi: 10.1038/s41467-018-03050-0.

5.

B-Cell Therapies in Multiple Sclerosis.

Sabatino JJ Jr, Zamvil SS, Hauser SL.

Cold Spring Harb Perspect Med. 2018 Jan 22. pii: a032037. doi: 10.1101/cshperspect.a032037. [Epub ahead of print]

PMID:
29358322
6.

The Gut Microbiome in Neuromyelitis Optica.

Zamvil SS, Spencer CM, Baranzini SE, Cree BAC.

Neurotherapeutics. 2018 Jan;15(1):92-101. doi: 10.1007/s13311-017-0594-z. Review.

7.

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4.

Sagan SA, Cruz-Herranz A, Spencer CM, Ho PP, Steinman L, Green AJ, Sobel RA, Zamvil SS.

J Vis Exp. 2017 Aug 21;(126). doi: 10.3791/56185.

8.

T cells targeting neuromyelitis optica autoantigen aquaporin-4 cause paralysis and visual system injury.

Cruz-Herranz A, Sagan SA, Sobel RA, Green AJ, Zamvil SS.

J Nat Sci. 2017 May;3(5). pii: e358.

9.

Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activity.

Sabatino JJ Jr, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e366. doi: 10.1212/NXI.0000000000000366. eCollection 2017 Jul. No abstract available.

10.

Acute liver injury in a Glatopa-treated patient with MS.

Sabatino JJ Jr, Mehta NJ, Kakar S, Zamvil SS, Cree BAC.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 5;4(4):e368. doi: 10.1212/NXI.0000000000000368. eCollection 2017 Jul. No abstract available.

11.

B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue.

Lehmann-Horn K, Wang SZ, Sagan SA, Zamvil SS, von Büdingen HC.

JCI Insight. 2016 Dec 8;1(20):e87234.

12.

Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4.

Sagan SA, Winger RC, Cruz-Herranz A, Nelson PA, Hagberg S, Miller CN, Spencer CM, Ho PP, Bennett JL, Levy M, Levin MH, Verkman AS, Steinman L, Green AJ, Anderson MS, Sobel RA, Zamvil SS.

Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14781-14786. doi: 10.1073/pnas.1617859114. Epub 2016 Dec 8.

13.

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.

Varrin-Doyer M, Pekarek KL, Spencer CM, Bernard CC, Sobel RA, Cree BA, Schulze-Topphoff U, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 21;3(5):e272. eCollection 2016 Oct.

14.

Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery.

Mei F, Lehmann-Horn K, Shen YA, Rankin KA, Stebbins KJ, Lorrain DS, Pekarek K, A Sagan S, Xiao L, Teuscher C, von Büdingen HC, Wess J, Lawrence JJ, Green AJ, Fancy SP, Zamvil SS, Chan JR.

Elife. 2016 Sep 27;5. pii: e18246. doi: 10.7554/eLife.18246.

15.

Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls.

Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, Spencer CM, Lynch SV, Zamvil SS, Waubant E; US Network of Pediatric MS Centers.

BMC Neurol. 2016 Sep 21;16(1):182.

16.

Restoring immune tolerance in neuromyelitis optica: Part II.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e277. doi: 10.1212/NXI.0000000000000277. eCollection 2016 Oct. Review.

17.

Restoring immune tolerance in neuromyelitis optica: Part I.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e276. doi: 10.1212/NXI.0000000000000276. eCollection 2016 Oct. Review.

18.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

19.

Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens.

Cree BA, Spencer CM, Varrin-Doyer M, Baranzini SE, Zamvil SS.

Ann Neurol. 2016 Sep;80(3):443-7. doi: 10.1002/ana.24718. Epub 2016 Aug 4.

20.

Antibodies in multiple sclerosis oligoclonal bands target debris.

Winger RC, Zamvil SS.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7696-8. doi: 10.1073/pnas.1609246113. Epub 2016 Jun 28. No abstract available.

21.

Your nose knows how to target brain inflammation.

Winger RC, Zamvil SS.

Brain. 2016 Jul;139(Pt 7):1866-9. doi: 10.1093/brain/aww121. No abstract available.

22.

Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2.

Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM, Shetty A, Sagan SA, Cree BA, Sobel RA, Wipke BT, Steinman L, Scannevin RH, Zamvil SS.

Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4777-82. doi: 10.1073/pnas.1603907113. Epub 2016 Apr 13.

23.

Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.

Steinman L, Zamvil SS.

Curr Opin Neurol. 2016 Jun;29(3):340-4. doi: 10.1097/WCO.0000000000000317. Review.

PMID:
27027554
24.

CNS accumulation of regulatory B cells is VLA-4-dependent.

Lehmann-Horn K, Sagan SA, Winger RC, Spencer CM, Bernard CC, Sobel RA, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 9;3(2):e212. doi: 10.1212/NXI.0000000000000212. eCollection 2016 Apr.

25.

Glatiramer acetate treatment negatively regulates type I interferon signaling.

Molnarfi N, Prod'homme T, Schulze-Topphoff U, Spencer CM, Weber MS, Patarroyo JC, Lalive PH, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 9;2(6):e179. doi: 10.1212/NXI.0000000000000179. eCollection 2015 Dec. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2015 Dec;2(6):e189.

26.

Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection.

Mowry EM, Pelletier D, Gao Z, Howell MD, Zamvil SS, Waubant E.

Eur J Neurol. 2016 Feb;23(2):327-32. doi: 10.1111/ene.12844. Epub 2015 Oct 31.

PMID:
26518224
27.

Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation.

Ryu JK, Petersen MA, Murray SG, Baeten KM, Meyer-Franke A, Chan JP, Vagena E, Bedard C, Machado MR, Rios Coronado PE, Prod'homme T, Charo IF, Lassmann H, Degen JL, Zamvil SS, Akassoglou K.

Nat Commun. 2015 Sep 10;6:8164. doi: 10.1038/ncomms9164.

28.

Unique invariant CD8(+) T cell population persists in MS.

Sabatino JJ Jr, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 27;2(4):e140. doi: 10.1212/NXI.0000000000000140. eCollection 2015 Aug. No abstract available.

29.

Erratum: The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis.

Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R, Prodhomme T, Duong B, Whang MI, Advincula R, Agelidis A, Barrera J, Wu H, Burlingame A, Malynn BA, Zamvil SS, Ma A.

Nat Immunol. 2015 Jul;16(7):785. doi: 10.1038/ni0715-785c. No abstract available.

30.

B lymphocytes in neuromyelitis optica.

Bennett JL, O'Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, von Büdingen HC, Stuve O, Yeaman MR, Smith TJ, Stadelmann C.

Neurol Neuroimmunol Neuroinflamm. 2015 May 7;2(3):e104. doi: 10.1212/NXI.0000000000000104. eCollection 2015 Jun. Review.

31.

The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis.

Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R, Prodhomme T, Duong B, Whang MI, Advincula R, Agelidis A, Barrera J, Wu H, Burlingame A, Malynn BA, Zamvil SS, Ma A.

Nat Immunol. 2015 Jun;16(6):618-27. doi: 10.1038/ni.3172. Epub 2015 May 4. Erratum in: Nat Immunol. 2015 Jul;16(7):785.

32.

Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.

von Büdingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS.

Eur Neurol. 2015;73(3-4):238-46. doi: 10.1159/000377675. Epub 2015 Mar 25. Review.

33.

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.

Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76. doi: 10.1212/NXI.0000000000000076. eCollection 2015 Jun.

34.

B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity.

Lehmann-Horn K, Sagan SA, Bernard CC, Sobel RA, Zamvil SS.

Ann Neurol. 2015 May;77(5):902-8. doi: 10.1002/ana.24387. Epub 2015 Mar 28.

35.

Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?

Zamvil SS, Slavin AJ.

Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62. doi: 10.1212/NXI.0000000000000062. eCollection 2015 Feb. Review.

36.

Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE.

Shetty A, Gupta SG, Varrin-Doyer M, Weber MS, Prod'homme T, Molnarfi N, Ji N, Nelson PA, Patarroyo JC, Schulze-Topphoff U, Fogal SE, Forsthuber T, Sobel RA, Bernard CC, Slavin AJ, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2014 Aug 14;1(2):e22. doi: 10.1212/NXI.0000000000000022. eCollection 2014 Aug.

37.

MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS.

Varrin-Doyer M, Shetty A, Spencer CM, Schulze-Topphoff U, Weber MS, Bernard CC, Forsthuber T, Cree BA, Slavin AJ, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2014 Aug 14;1(2):e20. doi: 10.1212/NXI.0000000000000020. eCollection 2014 Aug.

38.

Precision medicine in chronic disease management: The multiple sclerosis BioScreen.

Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL.

Ann Neurol. 2014 Nov;76(5):633-42. doi: 10.1002/ana.24282. Epub 2014 Oct 14. Review.

39.

Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.

Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U.

Exp Neurol. 2014 Dec;262 Pt A:66-71. doi: 10.1016/j.expneurol.2014.04.002. Epub 2014 Apr 13. Review.

40.

Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.

Weber MS, Prod'homme T, Youssef S, Dunn SE, Steinman L, Zamvil SS.

J Neuroinflammation. 2014 Feb 6;11:29. doi: 10.1186/1742-2094-11-29.

41.

MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies.

Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod'homme T, Varrin-Doyer M, Shetty A, Linington C, Slavin AJ, Hidalgo J, Jenne DE, Wekerle H, Sobel RA, Bernard CC, Shlomchik MJ, Zamvil SS.

J Exp Med. 2013 Dec 16;210(13):2921-37. doi: 10.1084/jem.20130699. Epub 2013 Dec 9.

42.

Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS.

JAMA Neurol. 2013 Oct;70(10):1315-24. Review.

43.

Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity.

Schulze-Topphoff U, Casazza S, Varrin-Doyer M, Pekarek K, Sobel RA, Hauser SL, Oksenberg JR, Zamvil SS, Baranzini SE.

J Exp Med. 2013 Jul 1;210(7):1301-9.

44.

The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis.

Cravens PD, Kieseier BC, Hussain R, Herndon E, Arellano B, Ben LH, Timmons BC, Castro-Rojas C, Hartung HP, Hemmer B, Weber MS, Zamvil SS, Stüve O.

J Neuroinflammation. 2013 May 24;10:67. doi: 10.1186/1742-2094-10-67.

45.

Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity.

Hertzenberg D, Lehmann-Horn K, Kinzel S, Husterer V, Cravens PD, Kieseier BC, Hemmer B, Brück W, Zamvil SS, Stüve O, Weber MS.

Eur J Immunol. 2013 Aug;43(8):2078-88. doi: 10.1002/eji.201343338. Epub 2013 Jun 3.

46.

Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter.

Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS.

Ann Neurol. 2012 Jul;72(1):53-64. doi: 10.1002/ana.23651. Epub 2012 Jul 17.

47.

Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.

Brück W, Zamvil SS.

Expert Rev Clin Pharmacol. 2012 May;5(3):245-56. doi: 10.1586/ecp.12.12. Review.

PMID:
22697588
48.

K+ channel alterations in the progression of experimental autoimmune encephalomyelitis.

Jukkola PI, Lovett-Racke AE, Zamvil SS, Gu C.

Neurobiol Dis. 2012 Aug;47(2):280-93. doi: 10.1016/j.nbd.2012.04.012. Epub 2012 Apr 24.

49.

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.

Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, Nelson PA, Zamvil SS.

PLoS One. 2012;7(3):e33797. doi: 10.1371/journal.pone.0033797. Epub 2012 Mar 30.

50.

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.

Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team.

Neurology. 2012 Apr 10;78(15):1171-8. doi: 10.1212/WNL.0b013e31824f7fdd. Epub 2012 Mar 28.

Supplemental Content

Loading ...
Support Center